Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ImmunityBio converts from Immunomedics -- Ignore unavailable to you. Want to Upgrade?

To: End2War who wrote (896)	3/1/2025 12:29:23 PM
From: Huggenberg	Respond to of 1229

To add: In the PR regarding lymphopenia and pancreatic cancer, TGFß is referenced: „Thus, there is a rationale for the combination of Anktiva (converting a cold tumor to hot tumor and rescuing T cells by re-expressing MHC-I) and PD-L1 t-haNK to overcome the immunosuppressive effect of TGFß secreted by MDSCs.“ The TGFß-trap mentioned in my previous post is based on HCW9218: https://www.reddit.com/r/IBRX/comments/1em6ahh/anktiva_and_the_tgfbeta_trap/ I don’t believe that HCW9218 is part of the BLA yet, but its ability to counteract the immunosuppressive effect of TGFß would be significantly greater than that of Anktiva and PD-L1 t-haNK alone.